抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3112人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1853015, encodeId=5228185301579, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=0, createdTime=2022-07-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852894, encodeId=ccb61852894fa, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, objectType=article, longId=299456, objectId=55f52994568e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f52994568e, replyNumber=0, likeNumber=119, createdTime=2022-06-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f52994568e, moduleTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55f52994568e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852926, encodeId=512d185292685, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Dig Dis Sci：出院后质子泵抑制剂的不当使用与再入院率增加有关, objectType=article, longId=301805, objectId=ce2d30180513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce2d30180513, replyNumber=0, likeNumber=68, createdTime=2022-06-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce2d30180513, moduleTitle=Dig Dis Sci：出院后质子泵抑制剂的不当使用与再入院率增加有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce2d30180513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852953, encodeId=49fc1852953ca, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, objectType=article, longId=725549, objectId=d86fe255493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d86fe255493e, replyNumber=0, likeNumber=87, createdTime=2023-02-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d86fe255493e, moduleTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d86fe255493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852899, encodeId=d243185289989, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=CEN Case Rep：肾素-血管紧张素-醛固酮系统抑制剂治疗高血压急症急性期并发急性肾损伤的案例分析, objectType=article, longId=299770, objectId=b4ff299e7057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4ff299e7057, replyNumber=0, likeNumber=91, createdTime=2022-06-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4ff299e7057, moduleTitle=CEN Case Rep：肾素-血管紧张素-醛固酮系统抑制剂治疗高血压急症急性期并发急性肾损伤的案例分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4ff299e7057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852893, encodeId=0c0b1852893c9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Expert Opin Investig Drugs：TNF抑制剂治疗强直性脊柱炎的疾病改善情况, objectType=article, longId=299357, objectId=9d9d29935e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d9d29935e26, replyNumber=0, likeNumber=70, createdTime=2022-03-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d9d29935e26, moduleTitle=Expert Opin Investig Drugs：TNF抑制剂治疗强直性脊柱炎的疾病改善情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d9d29935e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852934, encodeId=e5f11852934ed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD：巴瑞替尼（JAK抑制剂）治疗活动性干燥综合征的初步研究, objectType=article, longId=723469, objectId=e50ae23469ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e50ae23469ec, replyNumber=0, likeNumber=139, createdTime=2022-10-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e50ae23469ec, moduleTitle=ARD：巴瑞替尼（JAK抑制剂）治疗活动性干燥综合征的初步研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e50ae23469ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853032, encodeId=29041853032ca, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, objectType=article, longId=736106, objectId=5cc6e3610606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc6e3610606, replyNumber=0, likeNumber=65, createdTime=2023-07-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc6e3610606, moduleTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cc6e3610606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852898, encodeId=cdb81852898c9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响, objectType=article, longId=299714, objectId=365f299e146f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365f299e146f, replyNumber=0, likeNumber=81, createdTime=2022-11-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365f299e146f, moduleTitle=Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365f299e146f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852890, encodeId=1066185289074, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：EDP-938，一种呼吸道合胞病毒抑制剂效果如何？, objectType=article, longId=298993, objectId=0cb429899394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cb429899394, replyNumber=0, likeNumber=0, createdTime=2022-07-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cb429899394, moduleTitle=NEJM：EDP-938，一种呼吸道合胞病毒抑制剂效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cb429899394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853042, encodeId=ed931853042b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMC Cancer：肾素-血管紧张素系统抑制剂对直肠癌患者生存的影响, objectType=article, longId=737302, objectId=d133e37302ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d133e37302ca, replyNumber=0, likeNumber=107, createdTime=2023-07-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d133e37302ca, moduleTitle=BMC Cancer：肾素-血管紧张素系统抑制剂对直肠癌患者生存的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d133e37302ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852956, encodeId=d5d01852956a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？, objectType=article, longId=725783, objectId=0217e25783c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0217e25783c1, replyNumber=0, likeNumber=121, createdTime=2022-12-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0217e25783c1, moduleTitle=FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0217e25783c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852954, encodeId=5073185295455, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, objectType=article, longId=725589, objectId=2d1de25589ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d1de25589ae, replyNumber=0, likeNumber=0, createdTime=2022-07-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d1de25589ae, moduleTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d1de25589ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852950, encodeId=f02318529505a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, objectType=article, longId=724862, objectId=9d1fe248622b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d1fe248622b, replyNumber=0, likeNumber=87, createdTime=2022-08-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d1fe248622b, moduleTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d1fe248622b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852869, encodeId=42e21852869c8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=65, createdTime=2022-09-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852877, encodeId=9fca18528e7b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BJD：新生儿Fc受体抑制剂Efgartigimod治疗寻常型天疱疮和叶状天疱疮, objectType=article, longId=294991, objectId=c03429499136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c03429499136, replyNumber=0, likeNumber=85, createdTime=2022-10-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c03429499136, moduleTitle=BJD：新生儿Fc受体抑制剂Efgartigimod治疗寻常型天疱疮和叶状天疱疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c03429499136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852933, encodeId=9710185293329, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=0, createdTime=2022-04-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852892, encodeId=1776185289214, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：较低的自身抗体水平与免疫检查点抑制剂引起的免疫相关不良事件相关性研究, objectType=article, longId=299379, objectId=a0c12993e948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0c12993e948, replyNumber=0, likeNumber=0, createdTime=2022-03-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c12993e948, moduleTitle=J Immunother Cancer：较低的自身抗体水平与免疫检查点抑制剂引起的免疫相关不良事件相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0c12993e948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852915, encodeId=82c418529151d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, objectType=article, longId=301207, objectId=11cf30120ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cf30120ed4, replyNumber=0, likeNumber=69, createdTime=2022-12-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cf30120ed4, moduleTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cf30120ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853053, encodeId=243c185305322, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Hypertension：免疫检查点抑制剂不会增加癌症患者高血压的短期风险, objectType=article, longId=739236, objectId=b5fbe39236f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5fbe39236f4, replyNumber=0, likeNumber=95, createdTime=2022-11-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5fbe39236f4, moduleTitle=Hypertension：免疫检查点抑制剂不会增加癌症患者高血压的短期风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5fbe39236f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异

2022-06-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Dig Dis Sci：出院后质子泵抑制剂的不当使用与再入院率增加有关

2022-06-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂

2023-02-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

CEN Case Rep：肾素-血管紧张素-醛固酮系统抑制剂治疗高血压急症急性期并发急性肾损伤的案例分析

2022-06-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Expert Opin Investig Drugs：TNF抑制剂治疗强直性脊柱炎的疾病改善情况

2022-03-26

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ARD：巴瑞替尼（JAK抑制剂）治疗活动性干燥综合征的初步研究

2022-10-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素

2023-07-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响

2022-11-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：EDP-938，一种呼吸道合胞病毒抑制剂效果如何？

2022-07-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMC Cancer：肾素-血管紧张素系统抑制剂对直肠癌患者生存的影响

2023-07-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？

2022-12-03

仁医06 (审核中...)

前往app查看评论内容

#抑制剂#

Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系

2022-07-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益

2022-08-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-09-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BJD：新生儿Fc受体抑制剂Efgartigimod治疗寻常型天疱疮和叶状天疱疮

2022-10-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2022-04-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：较低的自身抗体水平与免疫检查点抑制剂引起的免疫相关不良事件相关性研究

2022-03-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究

2022-12-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Hypertension：免疫检查点抑制剂不会增加癌症患者高血压的短期风险

2022-11-13

科室
- - 订阅+
  - 更多科室
工具
服务